Table 3.
Treatment outcomes in all patients, those who had high-risk CA, and those who received different ixazomib-based regimens
| All patients (N = 85) | High-risk CAa (n = 15) | IRd regimen (n = 38) | Other triplet regimenb (n = 22) | Id doublet regimen (n = 25) | |
|---|---|---|---|---|---|
| Best confirmed responsec, n (%) | |||||
| ORR (≥ PR) | 81 (95.3) | 13 (86.7) | 35 (92.1) | 21 (95.5) | 25 (100.0) |
| ≥ VGPR | 56 (65.9) | 5 (33.3) | 22 (57.9) | 19 (86.3) | 15 (60.0) |
| CR | 25 (29.5) | 2 (13.3) | 10 (26.3) | 7 (31.8) | 8 (32.0) |
| PR | 56 (65.9) | 11 (73.3) | 25 (65.8) | 14 (63.6) | 17 (68.0) |
| VGPR | 31 (36.5) | 3 (20.0) | 12 (31.6) | 12 (54.5) | 7 (28.0) |
| MR | 1 (1.2) | 1 (6.7) | 1 (2.6) | 0 | 0 |
| SD | 3 (3.5) | 1 (6.7) | 2 (5.3) | 1 (4.5) | 0 |
| Median time to 1st response, months | 1.0 | 1.0 | 1.0 | 1.0 | 0.9 |
| Median time to best response, months | 2.1 | 1.9 | 2.3 | 2.5 | 1.8 |
| Median PFS, months | NE | NE | NE | NE | NE |
| 12-month PFS, % | 86.3 | 76.6 | 85.5 | 94.7 | 83.8 |
| Median OS, months | NE | NE | NE | NE | NE |
| 12-month OS, % | 95.3 | 100 | 100 | 95.6 | 89.7 |
| 24-month OS, % | 84.3 | 66.7 | 66.7 | 95.6 | 89.7 |
| Patients with progression, n (%) | 11 (12.9) | 4 (26.7) | 6 (15.8) | 1 (4.5) | 4 (16.0) |
CA, cytogenetic abnormalities; ORR, overall response rate; PR, partial response; VGPR, very good partial response; CR, complete response; MR, minimal response; SD, stable disease; PFS, progression-free survival; OS, overall survival; IRd, ixazomib plus lenalidomide and dexamethasone; Id, ixazomib plus dexamethasone; NE, not estimable
aHigh-risk CA included del 17, t(4;14), t(14;16)
bThis subgroup included Id plus another chemotherapeutics or monoclonal antibody: 11 cases with doxorubicin, 7 with cyclophosphamide, 3 with thalidomide, and 1 with daratumumab
cFor patients who proceeded to SCT and received further ixazomib maintenance therapy, the best response reported include response post SCT